Date: <u>8/27/2021</u>				
Your Name: Jeremy Chuang, MD				
Manuscript Title: Locally advanced anal small cell carcinoma with durable complete response to chemoradiatio				
followed by consolidation chemotherapy: case report and literature review				
Manuscript number (if known):				

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All and the same	Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	xNone	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	xNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	xNone	
4	Consulting fees	_xNone	

_				
5	Payment or honoraria for	xNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	_xNone		
	testimony			
7	Support for attending	xNone		
	meetings and/or travel			
8	Patents planned, issued or	x_None		
	pending			
9	Participation on a Data	x_None		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	xNone		
	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	xNone		
12	Receipt of equipment,	x None		
	naterials, drugs, medical			
	writing, gifts or other			
	services			
13	Other financial or non-	x_None		
	financial interests			
	iniancial interests			
Ple	Please summarize the above conflict of interest in the following box:			
_				
L				

Please place an "X" next to the following statement to indicate your agreement:

__x_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: <u>08/27/2021</u>				
Your Name: <u>Chor</u>	gkai Wang			
Manuscript Title:	Locally advanced anal small cell carcinoma with durable complete response to chemoradiation			
followed by consolidation chemotherapy				
Manuscript number (if known): JGO-21-434			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials, medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

		I		
5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus, manuscript writing or			
	educational events			
6	Payment for expert	XNone		
	testimony			
7	Support for attending	XNone		
	meetings and/or travel			
8	Patents planned, issued or	XNone		
	pending			
9	Participation on a Data	X None		
9	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role in other board, society,	XNone		
comn				
	committee or advocacy group, paid or unpaid			
11	Stock or stock options	X None		
12	Receipt of equipment,	XNone		
	materials, drugs, medical writing, gifts or other			
	services			
13	Other financial or non-	XNone		
	financial interests			
Ple	Please summarize the above conflict of interest in the following box:			
_				

Please place an "X" next to the following statement to indicate your agreement:

__X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: <u>8/27/2021</u>					
Your Name: \	/ishwas Parekh				
Manuscript Title:	Manuscript Title: Locally advanced anal small cell carcinoma with durable complete response to				
chemoradiation followed by consolidation chemotherapy					
Manuscript numb	per (if known): JGO-21-434				

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	Genentech	Payments made to me

<u> </u>			
5	Payment or honoraria for	_XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X None	
	testimony		
	•		
7	Support for attending	X None	
,	meetings and/or travel		
	meetings and/or traver		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	X None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	Stock of Stock options		
12	Receipt of equipment,	X None	
12	materials, drugs, medical	XNone	
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
13	financial interests	_XNone	
	illianciai interests		

Please summarize the above conflict of interest in the following box:

Pathology consultation for a clinical trial that is not in direct conflict of interest to the submitted manuscript; mentioned only to provide broad relationship/activities with the industry.

Please place an "X" next to the following statement to indicate your agreement:

_X__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: <u>8/27/2021</u>					
Your Name: <u>Marwaı</u>	n Fakih				
Manuscript Title:	Locally advanced anal small cell carcinoma with durable complete response to chemoradiation				
followed by consolidation chemotherapy					
Manuscript number (if k	(nown): JGO-21-434				

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	Amgen	Payment to institution
	any entity (if not indicated	Verastem Oncology	Payment to me
	in item #1 above).	AstraZeneca	Payment to institution
		Novartis	Payment to institution
3	Royalties or licenses	_XNone	
4	Consulting fees	Pfizer	Payment to me

		Taiho	Payment to me
		Array BioPharma	Payment to me
		Amgen	Payment to me
		Bayer	Payment to me
		Seattle Genetics	Payment to me
		GSK	Payment to me
		Mirati Therapeutics	Payment to me
		HalioDx	Payment to me
		Zhuhai Yufan Biotech	Payment to me
5	Payment or honoraria for	Amgen	Payment to me
3	lectures, presentations,	Guardant Health	Payment to me
	speakers bureaus, manuscript writing or educational events	Guardant neatti	Payment to me
6	Payment for expert	_X_None	
	testimony		
7	Support for attending meetings and/or travel	_XNone	
8	Patents planned, issued or	<u>X</u> _None	
	pending		
9	Participation on a Data	_XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_X_None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	V Nava	
11	Stock or stock options	_XNone	
12	Descript of any i	DNAC	Charles and American and the Line 1991
12	Receipt of equipment,	BMS	Study-related drugs provided to institution
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	_X_None	
	financial interests		

Please summarize the above conflict of interest in the following box:

Over the past 36 months -

Dr. Marwan Fakih has consulted for HalioDx, Mirati, Pfizer, Taiho, and Zhuhai Yufan Biotech. He has served on Advisory Boards for Amgen, Array Biopharma, Bayer, GSK, Mirati and Seattle Genetics. He has received Honoraria or participated in Speaker Bureaus for Amgen and Guardant Health.

Please place an "X" next to the following statement to indicate your agreement:	
x_ I certify that I have answered every question and have not altered the wording of any of the questions or form.	ı this